Bezafibrate 200 MG ( DrugBank: Bezafibrate )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	2

93. Primary biliary cholangitis

---

Clinical trials : 298 /  Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04751188 (ClinicalTrials.gov)	October 2, 2020	5/2/2021	A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis	Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response	Primary Biliary Cirrhosis	Drug: Bezafibrate 200 MG Oral Tablet;Drug: Placebo;Drug: Ursodeoxycholic Acid	Instituto Mexicano del Seguro Social	NULL	Active, not recruiting	18 Years	65 Years	All	11	Phase 3	Mexico
2	NCT04594694 (ClinicalTrials.gov)	October 2, 2019	14/7/2020	Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC	A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid	Primary Biliary Cholangitis	Drug: Obeticholic acid;Drug: Bezafibrate 200 MG;Drug: OCA Placebo;Drug: Bezafibrate 200 mg Placebo;Drug: Bezafibrate 400 MG;Drug: Bezafibrate 400 mg Placebo	Intercept Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	75	Phase 2	Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom